



NC DEPARTMENT OF
**HEALTH AND
HUMAN SERVICES**

ROY COOPER • Governor

KODY H. KINSLEY • Secretary

MARK BENTON • Deputy Secretary for Health

SUSAN KANSAGRA • Assistant Secretary for Public Health

Division of Public Health

September 7, 2023

MEMORANDUM

TO: Vaccines for Children (VFC) Program Participants

FROM: Carrie Blanchard, PharmD, MPH, Immunization Branch Interim Director

SUBJECT: MENVEO® one-vial and Prevnar 20® Now Available for Ordering

The purpose of this memo is to announce two new vaccine presentations, MENVEO® one-vial and Prevnar 20®, that are now available to order via the North Carolina Immunization Registry (NCIR) for VFC enrolled providers.

MENVEO® one-vial (NDC 58160-0827-30) is approved for use in individuals 10 years through 55 years of age for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. The one-vial presentation contains MENVEO® in a single vial with a pink cap and **does NOT require reconstitution.**

MENVEO® two-vial (NDC 58160-0955-09) will still be available in limited quantities. Although the two-vial presentation is indicated for use in individuals ages 2 months through 55 years, providers are encouraged to begin limiting use to children ages 2 months through 2 years at increased risk of meningococcal disease as this is the only product available for this age group. MENVEO® two-vial must be reconstituted prior to administration. Requests for the limited MENVEO® two-vial vaccine will have a minimum order size of 1 dose with a maximum request of 5 doses. See [CDC's guidance](#) on the use of MenACWY products, along with the [MENVEO® package insert](#) for additional information. MenQuadfi® continues to be available for ordering.

Prevnar 20® (Pneumococcal 20-valent Conjugant Vaccine; NDC 00005-2000-10) is replacing Prevnar 13®. Providers can either continue to use any remaining Prevnar 13® vaccines still on-hand through the expiration date per the [current CDC vaccine schedule](#) or waste remaining doses following [VFC wastage instructions](#). Providers who choose to waste Prevnar 13® doses to transition to Prevnar 20® now will not be penalized for such wastage.

An MMWR outlining the clinical indications for Prevnar 20® will be forthcoming in the next few weeks. Please review [ACIP's Recommendations](#) as well as the [Prevnar 20® package insert](#) for more information.

NC DEPARTMENT OF HEALTH AND HUMAN SERVICES • DIVISION OF PUBLIC HEALTH • IMMUNIZATION BRANCH

LOCATION: 5601 Six Forks Road, Raleigh, NC 27609

MAILING ADDRESS: 1917 Mail Service Center, Raleigh, NC 27699-1917

www.ncdhhs.gov • TEL: 919-707-5550 • FAX: 919-870-4824

AN EQUAL OPPORTUNITY / AFFIRMATIVE ACTION EMPLOYER

As a reminder, VAXNEUVANCE® (Pneumococcal 15-valent Conjugant Vaccine) continues to be available for ordering as well.

In health,

A handwritten signature in black ink that reads "Carrie Blanchard". The script is cursive and fluid.

Carrie Blanchard
Immunization Branch Interim Director